DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z9p4jj/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2013" report to their offering.
'Diabetic Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy.
- A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Oxford BioMedica plc
Novagali Pharma SA
Antisense Therapeutics Limited
RegeneRx Biopharmaceuticals, Inc.
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
OcuCure Therapeutics, Inc.
Gene Signal International SA.
Inotek Pharmaceuticals Corporation
Angstrom Pharmaceuticals, Inc.
FirstString Research, Inc.
Resolvyx Pharmaceuticals, Inc
Stelic Institute & Co.
Centocor Ortho Biotech, Inc.
Vascular Pharmaceuticals, Inc.
Targa Therapeutics Corp.
America Stem Cell, Inc.
Ampio Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/z9p4jj/diabetic
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.